Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins
This article was originally published in The Pink Sheet Daily
Executive Summary
Small molecule projects in development will be out-licensed, including the Phase I glucokinase activator NN9101.
You may also be interested in...
Novo Drops NovoSeven Stroke Program Following Phase III Failure
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
Novo Drops NovoSeven Stroke Program Following Phase III Failure
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
Novo Nordisk Licenses GKA Program To Innovator TransTech
Deal is part of Novo’s effort to focus on protein-based molecules.